Senopsys Marks 20 Years of Making Medicines Palatable for Patients Worldwide
Woburn, Mass., June 2, 2026 – Senopsys, a leader in developing palatable medicines through sensory science, today announced its 20th anniversary serving the global biopharmaceutical industry.
For two decades, the company has helped ensure taste is never a barrier to a medicine’s success by delivering taste assessment and taste-masking solutions that inform formulation strategy, reduce development risk, and improve patient acceptance.
Since its founding, Senopsys has partnered with biotech and pharmaceutical companies to address complex taste challenges across dosage forms and therapeutic indications for pediatric, geriatric, and special needs patient populations where compliance is critical.
“Palatability should never be the reason a medicine fails,” said Jeff Worthington, Founder and President of Senopsys. “For 20 years, our mission has been to bring rigorous sensory science into drug development so formulation teams can make confident, data-driven decisions early, when they have the greatest impact on timelines, cost, and patient outcomes.”
Senopsys’ human sensory testing and rapid prototyping provide sponsors with actionable insights not achievable through analytical or instrument-based methods alone. This capability has enabled clients to rescue at-risk programs, accelerate formulation selection, and design patient-acceptable dosage forms.
“What makes our work meaningful is the connection to the patient,” Worthington added. “Whether it’s a child refusing a bitter liquid, an oncology patient experiencing treatment fatigue, or a clinical study at risk because of poor acceptability, palatability directly affects health outcomes. We’re proud to have played a role in helping our clients bring more patient-friendly medicines to market.”
Over two decades, Senopsys has built a global reputation for solving multidimensional taste problems, including bitterness, oral irritation, malodor, and long aftertaste. Programs integrate sensory data into formulation design to meet regulatory, clinical, and commercial objectives.
“Reaching this 20-year milestone is a reflection of the trust our clients place in us,” said Worthington. “Many of our partnerships span multiple programs and years. That continuity has allowed us to refine a model that is both scientifically rigorous and highly responsive to the pace of modern drug development.”
As the industry continues to prioritize patient-centric design, Senopsys is expanding its capabilities to support new modalities, dosage forms, and increasingly complex molecules.
“The future of drug development is not only about proving efficacy and safety — it is also about creating medicines that patients are willing, and able, to take” Worthington said. “Our focus for the next decade is to deepen the integration of sensory science into mainstream pharmaceutical development so that palatability becomes a standard design parameter, not a late-stage rescue effort.”
ABOUT SENOPSYS
Senopsys is a specialty development company focused on making medicines palatable. Leveraging sensory science and deep taste-masking expertise, Senopsys partners with biopharmaceutical companies to develop patient-accepted oral dosage forms of investigational and approved drugs for children and adults.
Contact:
Jeff Worthington
Founder and President
Senopsys LLC
media@senopsys.com
+1 781-935-7450
www.senopsys.com